688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- 6.63
- +0.13+2.00%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. News
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (01349) will distribute a cash dividend of 0.07 yuan per share on July 12th.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) announced that it will distribute a cash dividend of 0... per share on July 12, 2024.
Fudan-Zhangjiang to Invest 200 Million Yuan in Structured Deposit Product
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) subscribed for 200 million yuan of a structured deposit product by Ping An Bank on Wednesday, a same-day bourse filing said. The product has an
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) subscribed to 200 million yuan of structured deposit products.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (01349.HK) announced on July 3 that the company has recently entered into a structured deposit product agreement with Ping An Bank. They have agreed to subscribe to a structured deposit product with a total amount of RMB 200 million using their own idle funds generated from daily operations.
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical- Co to Subscribe for Structured Deposit Product of RMB200 Mln
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Entered Into Spd Bank Structured Deposit Product Agreement With Shanghai Pudong Development Bank
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Agreed to Subscribe for Structured Deposit Product With Amount of RMB180 Mln
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Subscription of Structured Deposit Product Under Bank of China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) cancels part of the raised funds special account.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) announced that the "Acquisition of Minority Equity Interest in Fudan-Zhangjiang, Taizhou" fundraising project has been completed...
FUDANZHANGJIANG: POLL RESULTS OF 2023 ANNUAL GENERAL MEETING; AND DISTRIBUTION OF FINAL DIVIDEND
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) will distribute a final dividend of 0.07 yuan per share on August 26th.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) announced that it will distribute dividends as of January 2023 on August 26, 2024...
Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial
Shanghai Fudan Zhangjiang Bio-Pharmaceutical (SHA:688505) enrolled the first patient in a clinical trial for its aminolevulinic acid hydrochloride powder for oral solution, according to a Friday filin
Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement
Shanghai Fudan Zhangjiang Bio-Pharmaceutical (SHA:688505) terminated its 10-year marketing agreement with Huizheng (Shanghai) Pharmaceutical Technology to promote its product, Libod, according to a Th
Shanghai Fudan-Zhangjiang Terminates Marketing Agreement
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) has entered into a termination agreement with Shanghai Huizheng regarding the marketing service agreement and relevant supplementary agreements,
Shanghai Fudan-Zhangjiang Admits First Patient in Confirmatory Clinical Trial for Tumor Margin Visualization
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) enrolled the first patient in the confirmatory clinical trial of aminolevulinic acid hydrochloride powder for oral solution for intraoperative v
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Termination of Promotion Service Agreement With Shanghai Huizheng
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH): Powder for oral solution of ammonium ferrocyanide succinate hydrochloride was used for visual verification of glioma surgery, and the first subject was enrolled in the confirmatory clinica
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH) announced on June 20 that the company's orally-administered solution of Ammonium Levulinate and Butyrate Hydrochloride powder (referred to as "the drug") used for visualization in the surgery of high-grade glioma (WHO grade III-IV) that was developed through company research has completed its first successful validation clinical trial with the inclusion of test subjects.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) received government subsidy of RMB 10 million in Taizhou Fudan-Zhangjiang.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349) has announced that its subsidiary, Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taizhou...")
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Co to Subscribe for Structured Deposit Product of RMB100 Mln Under Shanghai Pudong Development Bank
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) subscribed to 100 million yuan Shanghai Pudong Development Bank structured deposit products.
On June 3rd, Gelon Hui reported that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) has entered into a structured deposit product agreement III with Shanghai Pudong Development Bank, agreeing to subscribe to a total amount of RMB 100 million structured deposit products using idle funds generated from daily operations.
Fudan Zhangjiang (01349.HK) was reduced by 364,000 shares by Invesco Hong Kong
Glonghui, May 13 | According to the Stock Exchange's latest equity disclosure data, on May 8, 2024, Fudan Zhangjiang (01349.HK) was reduced by 364,000 shares by Invesco Hong Kong Limited at an average price of HK$2.1664 per share, involving approximately HK$78,600. After reducing its holdings, Invesco Hong Kong Limited's latest shareholding was 16.16 million shares, and the shareholding ratio dropped from 5.06% to 4.95%.
Analysis
Price Target
No Data
